Navidea Biopharmaceuticals to Present at Biotech Showcase 2018
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it will be presenting at the Biotech Showcase in San Francisco, CA being held on January 8-10, 2018. Dr. Michael Goldberg, Chief Executive Officer of Navidea, will be giving a presentation and meeting with investors.
Event: Biotech Showcase™
Presentation Date: Monday, January 8, 2018
Presentation Time: 10:00 am PT
Location: Hilton San Francisco Union Square, San Francisco, CA
For investors attending the Biotech Showcase, please contact Navidea Investor Relations to schedule a meeting with management at firstname.lastname@example.org.
The presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the Investors presentations tab of the Investors section of the Navidea website at www.navidea.com.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts.
For more information, please visit www.navidea.com.
Source: Navidea Biopharmaceuticals, Inc.
Released December 19, 2017